Skip to main content
SpringerLink
Log in

Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

We report a case of clearance of persistent bacteremia due to daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus native mitral valve endocarditis with a combination of ceftaroline and daptomycin, in an 81-year-old medically complex patient who was not an operative candidate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Loomba PS, Taneja J, Mishra B. Methicillin and vancomycin resistant S. aureus in hospitalized patients. J Glob Infect Dis. 2010;2:275–83. doi:10.4103/0974-777X.68535.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis. 2012;55:582–6. doi:10.1093/cid/cis492.

    Article  CAS  PubMed  Google Scholar 

  3. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079–82. doi:10.1128/AAC.50.3.1079-1082.2006.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother. 2014;58:672–7. doi:10.1128/AAC.01516-13.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158–63. doi:10.1093/cid/cir340.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67:1267–70. doi:10.1093/jac/dks006.

    Article  CAS  PubMed  Google Scholar 

  7. Jongsma K, Joson J, Heidari A. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report. J Antimicrob Chemother. 2013;68:1444–5. doi:10.1093/jac/dkt009.

    Article  CAS  PubMed  Google Scholar 

  8. Murthy MH, Olson ME, Wickert RW, Fey PD, Jalali Z. Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol. 2008;57:1036–8. doi:10.1099/jmm.0.2008/000588-0.

    Article  PubMed  Google Scholar 

  9. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014. doi:10.1016/j.clinthera.2014.05.061.

    Google Scholar 

  10. Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents. 2013;42:450–5. doi:10.1016/j.ijantimicag.2013.07.005.

    Article  CAS  PubMed  Google Scholar 

  11. Tattevin P, Boutoille D, Vitrat V, Van Grunderbeeck N, Revest M, Dupont M, et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother. 2014;69:2010–3. doi:10.1093/jac/dku085.

    Article  CAS  PubMed  Google Scholar 

  12. Fabre V, Ferrada M, Buckel WR, Avdic E, Cosgrove SE. Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. Open Forum Infect Dis. 2014;1(2):ofu046. doi:10.1093/ofid/ofu046.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19:42–9. doi:10.1007/s10156-012-0449-9.

    Article  PubMed  Google Scholar 

  14. Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrob Agents Chemother. 2010;54:5376–8. doi:10.1128/AAC.00857-10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Yu R, Dale SE, Yamamura D, Stankus V, Lee C. Daptomycin-nonsusceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus endocarditis. Can J Infect Dis Med Microbiol. 2012;23:e48–50.

    PubMed Central  PubMed  Google Scholar 

  16. Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A, et al. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother. 2007;51:3445–8. doi:10.1128/AAC.00559-07.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient—a review of the literature. Eur J Clin Microbiol Infect Dis. 2011;30:603–10. doi:10.1007/s10096-010-1128-3.

    Article  PubMed  Google Scholar 

  18. Ahmad NM, Rojtman AD. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin. Ann Pharmacother. 2010;44:918–21. doi:10.1345/aph.1M665.

    Article  PubMed  Google Scholar 

  19. Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:3162–5. doi:10.1128/AAC.00093-09.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Nadarajah R, Post LR, Liu C, Miller SA, Sahm DF, Brooks GF. Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods. Am J Clin Pathol. 2010;133:844–8. doi:10.1309/AJCPMV1P0VKUAZRD.

    Article  PubMed  Google Scholar 

  21. Werth BJ, Steed ME, Kaatz GW, Rybak MJ. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the “seesaw effect”. Antimicrob Agents Chemother. 2013;57:2664–8. doi:10.1128/AAC.02308-12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Barber KE, Ireland CE, Bukavyn N, Rybak MJ. Observation of “seesaw effect” with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. Infect Dis Ther. 2014;3:35–43. doi:10.1007/s40121-014-0023-0.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by UCSF Traineeship in AIDS Prevention Studies, National Institutes of Health [T32 MH-19105] to S.M.B. and National Institutes of Health [UCSF-CTSI KL2TR000143] to V.J.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, Med Science, Room S380, San Francisco, CA, 94143, USA

    Sanjiv M. Baxi

  2. Center for AIDS Prevention Studies, University of California, San Francisco, San Francisco, CA, USA

    Sanjiv M. Baxi

  3. Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA

    Dominic Chan

  4. Division of HIV/AIDS, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA

    Vivek Jain

Authors
  1. Sanjiv M. Baxi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dominic Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vivek Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sanjiv M. Baxi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baxi, S.M., Chan, D. & Jain, V. Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature. Infection 43, 751–754 (2015). https://doi.org/10.1007/s15010-015-0763-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-015-0763-0

Keywords

Search

Navigation